Innovative Vaccines to Fight COVID-19, Other Viruses

COVID-19 added urgency to the quest for the development of new vaccines, and academic researchers and biotechnology companies responded by capitalizing on already-in-the-pipeline advances and swiftly transitioning products from the lab to the clinic. Their efforts reaped rewards. According to a U.S....

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IEEE 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905606/
https://www.ncbi.nlm.nih.gov/pubmed/34982663
http://dx.doi.org/10.1109/MPULS.2021.3128986
Descripción
Sumario:COVID-19 added urgency to the quest for the development of new vaccines, and academic researchers and biotechnology companies responded by capitalizing on already-in-the-pipeline advances and swiftly transitioning products from the lab to the clinic. Their efforts reaped rewards. According to a U.S. Department of Health and Human Services analysis, the COVID vaccines delivered in the USA from January to May 2021 resulted in 39,000 fewer deaths and 107,000 fewer hospitalizations, and prevented another 265,000 cases among Medicare recipients alone [1].

Ejemplares similares